1/22
Looks like no tags are added yet.
Cytochrome P450 hydroxylation mechanism
CYP enzymes inset 1 atom of molecule O2 into RH substrate = hydroxylated product (ROH), while other O2 atom is reduced to H2O (hydrophobic → hydrophilic)
Substrate (drug RH) binds to CYP haem iron (Fe3+) in enzyme’s active site = conformational change
Fe3+ reduced to Fe2+ via NADPH dependent reductase, allowing O2 to bind
O2 binds to Fe2+ - substrate complex
Second electron reduction and protonation (H+) cleaves O-O bond → releasing H2O and forms highly reactive iron-oxo species (Compound I/ FeO3+)
Compound I abstracts a H atom from substrate and inserts an OH group → hydroxylated product (more polar = increases drug solubility for Phase II)
Hydroxylated drug released and restores Fe3+ resting enzyme state
CYP roles
Convert lipophilic compounds (xenobiotics) into more polar molecules, facilitating subsequent Phase II conjugation and excretion
Hormone metabolism
CYP-mediated metabolism in bioactivation, generating reactive intermediates that may be carcinogenic (procarcinogens → highly reactive electrophilic carcinogenic products)
1* allele
Reference or wild type with normal function
2* or 3*
Enzyme doesn’t work properly → reduced or absent enzyme activity = loss of function = decreased drug metabolism
17*
Increased enzyme activity (gain of function)
Star alleles significance
Used to classify genetic variants of drug-metabolising enzymes, particularly CYP enzymes
CYP enzymes roles
Metabolise xenobiotics - foreign compounds not essential for homeostasis
Bioactivation - generating reactive intermediates that may be carcinogenic (procarcinogens → highly reactive electrophilic carcinogenic products)
Facilitate Phase II conjugation and excretion
How is CYP enzymes highly varaible?
Due to genetic polymorphisms and environmental influences = a major determinant of interindividual variability in drug response
What do genetic polymorphisms and variability in CYP enzymes do?
Significantly impact enzyme activity and are a major cause of variable drug response → influences drug metabolism and therapeutic outcomes
Genetic variants
Single nucleotide polymorphisms (SNPs)
Genetic deletions
Copy number variants (CNVs)
What do genetic variants do?
Alter enzyme structure or expression → phenotypes ranging from poor to ultra rapid metabolisers
Poor metabolisers
Have little or no enzyme activity
Resulting from combinations of “no function” alleles
Often necessitates dosage adjustment, avoiding excess bioavailability
Increased drug levels and toxicity
Intermediate metabolisers
Enzyme activity reduced → variable response
Extensive metabolisers
Normal enzyme activity → expected response
Ultra-rapid metabolisers
Very high enzyme activity due to gene duplication → decreased / subtherapeutic drug levels (breaks down drug quickly) → treatment failure
Why is variability important?
Important for drugs with narrow therapeutic indices and for prodrugs requiring metabolic activation
Guides personalised drug therapy
Phenotypic nomenclature
Describes how genetic variation in drug metabolising enzymes (CYP) translates into observable metabolic capacity - translates an individuals genetic makeup into observable metabolic capacities
Allows clinicians to predict how a patient will process medications
How does phenotypic nomenclature work?
Based on individuals phenotype, composed of alleles inherited from each parent, forms haplotypes and diplotypes which determine enzyme activity levels
Based on this, patients are classified into phenotypes: poor, intermediate, extensive or ultra rapid metabolisers
Star allele system significance
Used to classify genetic variants (specific haplotypes) of drug metabolising enzymes (CYP) that influence drug metabolism
Phase II metabolism
Detoxification process involving conjugation reactions with enzymes (UGTS, SULTS, etc) that attach large endogenous polar groups (glucuronic acid or sulfate) to drugs or Phase I metabolites
Increase water excretion and facilitate excretion
Generally produce inactive, non-toxic metabolites
Key enzymes in Phase II
UGTs - UDP- Glucuronosyltransferases
SULTs - sulfotransferases
GSTs - glutathione S-transferases
Phase III function
Use membrane transport proteins to facilitate movement and actively pump water soluble metabolites from kidneys, liver and intestines into bile, urine or intestinal lumen for excretion
Final conjugates rate eliminated primarily in kidneys (urine) and liver (bile → faeces)
2 transporters in phase iii
ATP-binding cassette (ABC) transporters - use energy from ATP hydrolysis to actively transport substrates against their concetration gradients (energy dependent) - over expression of abc transporters in tumour cells is main mechanism of tumour multidrug resistance (TMR)
Solute carrier (SLC) transporters - use membrane-bound proteins which rely on existing ion gradients to transport intracellular nutrients and metabolites = influences activity and potency of cytotoxic drugs